Angiex CEO Paul Jaminet Explores Cancer Therapies on The Pharmacist’s Edit Podcast
In this episode of The Pharmacist’s Edit, Paul Jaminet, CEO of Angiex, delves into the science behind Angiex’s pioneering TM4SF1-targeted antibody-drug conjugates (ADCs). These innovative therapies aim to treat aggressive cancers by disrupting tumor blood vessels. Jaminet also shares his insights on the challenges of advancing novel cancer treatments from early research through clinical trials, providing a comprehensive look at the company’s unique approach to oncology.
The Pharmacist’s Edit is hosted by Therese L’Seow, a clinical pharmacist with a passion for educating healthcare professionals on the latest advancements in medicine. With her background in both clinical pharmacy and medical writing, Therese brings a unique perspective to the podcast, offering thoughtful interviews with industry leaders and innovators. Her podcast is a platform for healthcare professionals to explore cutting-edge topics in pharmaceuticals and clinical care.
This episode gives listeners a deeper understanding of Angiex’s groundbreaking work in cancer therapy, while also exploring the broader challenges of bringing novel treatments to market. Through Therese’s engaging questions and Jaminet’s expertise, the conversation provides a compelling look at the future of cancer care.